| Christiane K Korba, MD | |
|
901 Patients First Dr, Washington, MO 63090-4700 | |
| (636) 390-9555 | |
| (636) 390-0114 |
| Full Name | Christiane K Korba |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 33 Years |
| Location | 901 Patients First Dr, Washington, Missouri |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1164464426 | NPI | - | NPPES |
| 208009316 | Medicaid | MO | |
| P00067152 | Other | RAILROAD MEDICARE | |
| P01135227 | Other | MO | RAILROAD MEDICARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 107695 (Missouri) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mercy Hospital Washington | Washington, MO | Hospital |
| Mercy Hospital St Louis | Saint louis, MO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mercy Clinic East Communities | 7214827922 | 491 |
News Archive
Patients care about how well pain, nausea, or treatment side effects are managed when evaluating the quality of the medical care they receive, but information about these experiences is not generally collected. To incorporate the values that patients care most about into formal assessments of provider and health system performance, a UNC Lineberger Comprehensive Cancer Center researcher led an expert panel to create a playbook on how to best develop, analyze and use patient-focused measures.
In recent years, improvements in cancer therapy have led to a significant increase in cancer survivorship. Experts estimate that by 2022, the United States will have 18 million cancer survivors, but a subset of those survivors will have long-term health problems to be addressed.
Mayo Clinic today announced plans to establish the Mayo Clinic Proton Beam Therapy Program as part of Mayo's national three-site cancer center in Minnesota, Arizona and Florida. The new program will employ intensity modulated proton therapy — based on pencil beam scanning — which is a more precise form of proton therapy treatment that allows greater control over radiation doses, shorter treatment times and fewer side effects. It is also believed to be more cost effective in selected patients.
Cerus Corporation announced today that the FDA's Blood Products Advisory Committee (BPAC) rendered a positive opinion on the proposed hemostatic efficacy and safety endpoints for a potential U.S. Phase III clinical trial of the INTERCEPT Blood System for platelets.
› Verified 7 days ago
| Entity Name | Mercy Clinic East Communities |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073739041 PECOS PAC ID: 7214827922 Enrollment ID: O20070521000058 |
News Archive
Patients care about how well pain, nausea, or treatment side effects are managed when evaluating the quality of the medical care they receive, but information about these experiences is not generally collected. To incorporate the values that patients care most about into formal assessments of provider and health system performance, a UNC Lineberger Comprehensive Cancer Center researcher led an expert panel to create a playbook on how to best develop, analyze and use patient-focused measures.
In recent years, improvements in cancer therapy have led to a significant increase in cancer survivorship. Experts estimate that by 2022, the United States will have 18 million cancer survivors, but a subset of those survivors will have long-term health problems to be addressed.
Mayo Clinic today announced plans to establish the Mayo Clinic Proton Beam Therapy Program as part of Mayo's national three-site cancer center in Minnesota, Arizona and Florida. The new program will employ intensity modulated proton therapy — based on pencil beam scanning — which is a more precise form of proton therapy treatment that allows greater control over radiation doses, shorter treatment times and fewer side effects. It is also believed to be more cost effective in selected patients.
Cerus Corporation announced today that the FDA's Blood Products Advisory Committee (BPAC) rendered a positive opinion on the proposed hemostatic efficacy and safety endpoints for a potential U.S. Phase III clinical trial of the INTERCEPT Blood System for platelets.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Christiane K Korba, MD 901 Patients First Dr, Washington, MO 63090-4700 Ph: (636) 390-9555 | Christiane K Korba, MD 901 Patients First Dr, Washington, MO 63090-4700 Ph: (636) 390-9555 |
News Archive
Patients care about how well pain, nausea, or treatment side effects are managed when evaluating the quality of the medical care they receive, but information about these experiences is not generally collected. To incorporate the values that patients care most about into formal assessments of provider and health system performance, a UNC Lineberger Comprehensive Cancer Center researcher led an expert panel to create a playbook on how to best develop, analyze and use patient-focused measures.
In recent years, improvements in cancer therapy have led to a significant increase in cancer survivorship. Experts estimate that by 2022, the United States will have 18 million cancer survivors, but a subset of those survivors will have long-term health problems to be addressed.
Mayo Clinic today announced plans to establish the Mayo Clinic Proton Beam Therapy Program as part of Mayo's national three-site cancer center in Minnesota, Arizona and Florida. The new program will employ intensity modulated proton therapy — based on pencil beam scanning — which is a more precise form of proton therapy treatment that allows greater control over radiation doses, shorter treatment times and fewer side effects. It is also believed to be more cost effective in selected patients.
Cerus Corporation announced today that the FDA's Blood Products Advisory Committee (BPAC) rendered a positive opinion on the proposed hemostatic efficacy and safety endpoints for a potential U.S. Phase III clinical trial of the INTERCEPT Blood System for platelets.
› Verified 7 days ago
Dr. Kenneth K Hamai, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 851 E 5th St, Suite 328, Washington, MO 63090 Phone: 636-239-1101 Fax: 636-239-0250 | |
Ann Libs, WHNP Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 851 E 5th St, Suite 200, Washington, MO 63090 Phone: 636-239-8585 Fax: 636-239-8553 | |
Robert D. Haskins Jr., M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 851 E 5th St, Suite 328, Washington, MO 63090 Phone: 636-239-1101 Fax: 636-239-0250 | |
Dr. Christy R Bleckman, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 851 E 5th St, Suite 328, Washington, MO 63090 Phone: 636-239-1101 Fax: 636-239-0250 | |
Dr. D. Bruce Glover Jr., D.O. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 851 E 5th St, Suite 328, Washington, MO 63090 Phone: 636-239-1101 | |
Gregory A. Potts, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 851 E 5th St, Suite 328, Washington, MO 63090 Phone: 636-239-1101 Fax: 636-239-0250 |